6533b85ffe1ef96bd12c0fa0
RESEARCH PRODUCT
Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer
Francesco MoschellaFrancesco DieliAlfredo SalernoEliana GulottaSerena MeravigliaGaspare GulottaNadia CaccamoAdriana CordovaGiuseppe Cicerosubject
Pharmacologybusiness.industrymedicine.medical_treatmentT cellOrganic ChemistryCancerEndogenyImmunotherapyT lymphocytemedicine.diseaseBiochemistrymedicine.anatomical_structureMechanism of actionAntigenIn vivoDrug DiscoveryImmunologymedicineMolecular Medicinemedicine.symptombusinessdescription
Several observations in mice and in humans have collectively laid the foundation for examining the potential of γ δ T cells to exert tumor immunotherapy. Human γ δ T cells can be activated in a non-MHC dependent fashion either by low molecular mass phosphoantigens, or by agents that provoke the accumulation of endogenous pyrophosphates such as isopentenylpyrophosphate. Among the latter, aminobisphosphonates are well-established in the clinic, and extensive data are available on the compounds antiangiogenic, antiosteolytic and pro-apoptotic properties. In this review we discuss on the possibility that the intentional activation of γ δ T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in patients with different types of cancer.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2008-05-01 | Current Medicinal Chemistry |